First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II tri
3 months ago
- #Clinical Trial
- #NSCLC
- #EGFR-mutant
- The ATTENTION study evaluated aumolertinib plus apatinib vs. aumolertinib alone in untreated, EGFR-mutant, advanced NSCLC.
- Combination therapy showed superior 18-month PFS rate (74% vs. 50%), median PFS (NR vs. 20.1 months), and objective response rate (79% vs. 59%).
- Grade 3 TRAEs were more common in the combination arm (38% vs. 27%), with hypertension and platelet count decrease being most frequent.
- PFS benefits from the combination were more pronounced in patients with TP53 mutations.
- The combination of aumolertinib and apatinib demonstrated manageable safety and efficacy as an infusion-free option.